NovoCure Limited (NVCR)

NovoCure Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
Cash & Equivalents	87.53	93.55	163.77	240.82
Short-Term Investments	344.48	354.13	796.11	669.8
Cash & Short-Term Investments	432	447.67	959.87	910.62
Cash Growth	-53.51%	-53.36%	5.41%	-
Accounts Receivable	93.27	89.44	74.23	61.22
Inventory	43.46	41.11	35.09	38.15
Other Current Assets	62.93	68.51	37.39	24.42
Total Current Assets	631.66	646.73	1,107	1,034
Net Property, Plant & Equipment	145.06	147	119.59	97.7
Other Long-Term Assets	11.2	10.6	14.62	14.02
Total Assets	787.93	804.33	1,241	1,146
Accounts Payable	127.24	122.23	105.09	94.39
Accrued Expenses	90.34	101	93.15	84.72
Current Portion of Long-Term Debt	-	-	558.16	-
Total Current Liabilities	217.58	223.23	756.39	179.12
Long-Term Debt	195.46	195.05	97.3	568.82
Long-Term Leases	39.48	41.65	19.97	27.42
Other Long-Term Liabilities	4.69	3.94	6.94	8.28
Total Long-Term Liabilities	239.63	240.63	124.21	604.52
Total Liabilities	457.21	463.86	880.61	783.63
Additional Paid-in Capital	1,697	1,634	1,520	1,353
Accumulated Other Comprehensive Income	-4.9	-3.44	-5.5	-5.47
Retained Earnings	-1,362	-1,290	-1,154	-985.5
Shareholders' Equity	330.72	340.47	360.18	362.5
Total Liabilities & Equity	787.93	804.33	1,241	1,146
Total Debt	234.94	236.69	675.43	596.24
Net Cash (Debt)	197.06	210.98	284.44	314.37
Net Cash Growth	-6.60%	-25.83%	-9.52%	-
Net Cash Per Share	1.75	1.89	2.64	2.96
Book Value	330.72	340.47	360.18	362.5
Book Value Per Share	2.94	3.05	3.34	3.41
Tangible Book Value	330.72	340.47	360.18	362.5
Tangible Book Value Per Share	2.94	3.05	3.34	3.41

Updated Apr 30, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q